MX2020002004A - Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. - Google Patents

Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.

Info

Publication number
MX2020002004A
MX2020002004A MX2020002004A MX2020002004A MX2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A
Authority
MX
Mexico
Prior art keywords
alcoholic
invasive diagnostic
fatty liver
liver fibrosis
alcoholic fatty
Prior art date
Application number
MX2020002004A
Other languages
English (en)
Inventor
Rémy Hanf
John Brozek
Geneviève Cordonnier
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2020002004A publication Critical patent/MX2020002004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un nuevo método no invasivo para el diagnóstico de una esteatosis hepática no alcohólica, en particular, esteatohepatitis no alcohólica y/o fibrosis hepática.
MX2020002004A 2017-08-25 2018-08-27 Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. MX2020002004A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306098 2017-08-25
EP17200028 2017-11-03
PCT/EP2018/073050 WO2019038456A1 (en) 2017-08-25 2018-08-27 NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS

Publications (1)

Publication Number Publication Date
MX2020002004A true MX2020002004A (es) 2020-10-05

Family

ID=63254739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002004A MX2020002004A (es) 2017-08-25 2018-08-27 Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.

Country Status (13)

Country Link
US (1) US20200248261A1 (es)
EP (1) EP3673078A1 (es)
JP (2) JP2020531023A (es)
KR (1) KR20200040848A (es)
CN (1) CN111032884A (es)
AU (1) AU2018320715A1 (es)
BR (1) BR112020003573A2 (es)
CA (1) CA3070038A1 (es)
IL (1) IL272869A (es)
MX (1) MX2020002004A (es)
PH (1) PH12020500164A1 (es)
SG (1) SG11202000748TA (es)
WO (1) WO2019038456A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020182952A1 (en) * 2019-03-13 2020-09-17 Genfit Diagnosis of non-alcoholic steatohepatitis
CN110346555B (zh) * 2019-06-04 2022-11-08 西安医学院 一种肝脏脂质代谢调控fxr蛋白硫氢化修饰的检测方法及应用
CA3140435A1 (en) * 2019-06-07 2020-12-10 Genfit Method for treatment of at risk patients
CA3187071A1 (en) * 2020-08-03 2022-02-10 Zouher Majd Method for nash risk assessment
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR102679687B1 (ko) 2021-04-06 2024-06-28 곽민진 비-알코올성 지방간염 비-인간 동물모델의 제조를 위한 조성물 및 이의 용도
CN116577509A (zh) * 2022-02-10 2023-08-11 香港中文大学深圳研究院 非酒精性脂肪性肝炎生物标志物组合物及其应用
EP4349918A1 (en) * 2022-10-06 2024-04-10 Sika Technology AG Method for producing batch material comprising renewable raw materials and bitumen for acoustic damping compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105826A1 (en) * 2011-02-01 2012-08-09 Erasmus University Medical Center Rotterdam Use of micrornas in diagnosis and therapy of aging
WO2013071502A1 (en) * 2011-11-17 2013-05-23 Genedia Biotech Co Ltd Mir-193a-3p and associated genes predict tumorigenesis and chemotherapy outcomes
JP2018518169A (ja) * 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
EP3350341B1 (en) 2015-09-14 2021-08-11 Genfit Methods for diagnosing and evaluating non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
CA3070038A1 (en) 2019-02-28
WO2019038456A1 (en) 2019-02-28
SG11202000748TA (en) 2020-03-30
PH12020500164A1 (en) 2020-09-14
CN111032884A (zh) 2020-04-17
US20200248261A1 (en) 2020-08-06
JP2020531023A (ja) 2020-11-05
EP3673078A1 (en) 2020-07-01
AU2018320715A1 (en) 2020-02-13
BR112020003573A2 (pt) 2020-09-01
KR20200040848A (ko) 2020-04-20
IL272869A (en) 2020-04-30
JP2023118802A (ja) 2023-08-25

Similar Documents

Publication Publication Date Title
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
PH12020500354A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
PH12018502057A1 (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3454745A4 (en) PERSONALIZATION OF THE DIAGNOSIS IN TERMS OF HEALTH AND ILLNESS
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MD4733C1 (ro) Anticorpi anti-TIGIT
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2020011099A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
EP3088898A4 (en) Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents
WO2017066712A3 (en) Modulators of telomere disease
WO2017066796A3 (en) Modulators of telomere disease
SG11202102684VA (en) Treatment for non-alcoholic fatty liver disease
EP3846843A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASES
MX2019000677A (es) Células miméticas de células b.
WO2017029558A3 (en) Methods for improving health of farmed fish
WO2016183223A3 (en) Targeted protein contrast agents, methods of making, and uses thereof
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
EP3470091A4 (en) NON-INVASIVE DIAGNOSTIC IMAGING AGENT FOR CARDIAC DISEASE
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
MX2021010475A (es) Diagnostico de esteatohepatitis no alcoholica.
EP3876946A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF VIRGIN DISEASE AND CARDIOPULMONARY DISEASES
EA202090569A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени